Cargando…
Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are approved treatments for non-small-cell lung cancer (NSCLC) patients harboring activating EGFR mutations. The EGFR C797S mutation is one of the known acquired-resistance mutations to the latest third-generation TKIs. At pre...
Autores principales: | Huang, Kuo-Yen, Wang, Tong-Hong, Chen, Chin-Chuan, Leu, Yann-Lii, Li, Hsin-Jung, Jhong, Cai-Ling, Chen, Chi-Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470952/ https://www.ncbi.nlm.nih.gov/pubmed/34572484 http://dx.doi.org/10.3390/biom11091271 |
Ejemplares similares
-
Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer
por: Wang, Tong-Hong, et al.
Publicado: (2020) -
Hydroxygenkwanin Suppresses Non-Small Cell Lung Cancer Progression by Enhancing EGFR Degradation
por: Leu, Yann-Lii, et al.
Publicado: (2020) -
Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
por: Duggirala, Krishna Babu, et al.
Publicado: (2022) -
Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M
por: Thress, Kenneth S., et al.
Publicado: (2015) -
Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo
por: Lai, Mengzhen, et al.
Publicado: (2023)